Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Galantamine clearance of amyloid-beta

A technology of amyloid and galantamine, which is applied in the directions of medical preparations containing active ingredients, drug combinations, active ingredients of heterocyclic compounds, etc.

Inactive Publication Date: 2018-03-27
SYNAPTEC DEV
View PDF9 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite a long-standing need to treat many of these conditions, there is only one drug on the market, varenicline, a partial nicotinic agonist and it is used for smoking cessation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Galantamine clearance of amyloid-beta
  • Galantamine clearance of amyloid-beta
  • Galantamine clearance of amyloid-beta

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0081] A method for determining an appropriate dose range for galantamine can be achieved by evaluating in vitro the concentration that improves Aβ oligomer clearance, and doing so with a concentration that protects the neurite network from residual oligomer damage. adjust. Galantamine or a pharmaceutically acceptable salt is then administered to experimental animals to determine plasma and brain concentrations, and to apply plasma concentrations related to effective brain concentrations to human subjects. To determine appropriate doses of galantamine for groups of subjects with varying degrees of cognitive impairment, counter-regulatory increases in CSF acetylcholinesterase can be determined. The dose of galantamine will be determined when the increase in CSF acetylcholinesterase does not exceed the increase in CSF acetylcholinesterase when 16 to 24 mg of galantamine is administered to a subject with Alzheimer's dementia Suitable, as demonstrated by Nordberg et al., 2009, su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Galantamine and its pharmaceutically acceptable salts are of use in treating persons meeting criteria for having a risk of developing Alzheimer's type dementia, before dementia occurs by reducing thedecline of A[beta] amyloid in CSF or the increase in cortical beta amyloid, in order to delay cognitive decline.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application 62 / 163,259, filed May 18, 2015, the contents of which are incorporated herein by reference. field of invention [0003] The present invention relates to slowing cognition and / or function in persons at risk of developing Alzheimer's dementia but not yet suffering from Alzheimer's dementia by increasing the clearance of toxic Aβ oligomers or reducing the deposition of Aβ method of decay. Background of the invention [0004] Plaques have long been known to be present in the brains of people with Alzheimer's disease (AD). However, the role of such plaques in the etiology of the disease has been unclear. [0005] In the 1980s, it was discovered that the plaques contained β-amyloid (Aβ), the sequence of which led to the cloning of the parent molecule amyloid precursor protein (APP). The soluble form of A[beta] is a multifunctional peptide that is beli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55C07D223/14A61P25/28
CPCA61K31/55A61K45/06A61P25/28A61K2300/00
Inventor B·M·戴维斯
Owner SYNAPTEC DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com